Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The advanced glycosylation end product (AGE) receptor encoded by AGER is a member of the immunoglobulin superfamily of cell surface receptors. Additionally we are shipping Advanced Glycosylation End Product-Specific Receptor Kits (79) and Advanced Glycosylation End Product-Specific Receptor Proteins (38) and many more products for this protein.
Showing 10 out of 318 products:
Cow (Bovine) Polyclonal AGER Primary Antibody for EIA, IHC (p) - ABIN264840
Sugars, Karlström, Christersson, Olsson, Wendel, Fried: Expression of HMGB1 during tooth development. in Cell and tissue research 2007
Show all 5 references for ABIN264840
Human Polyclonal AGER Primary Antibody for IHC (p), WB - ABIN389027
Schlueter, Hauke, Flohr, Rogalla, Bullerdiek: Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? in Biochimica et biophysica acta 2003
Show all 4 references for ABIN389027
Human Polyclonal AGER Primary Antibody for IF, IHC (p) - ABIN1108826
Bierhaus, Haslbeck, Humpert, Liliensiek, Dehmer, Morcos, Sayed, Andrassy, Schiekofer, Schneider, Schulz, Heuss, Neundörfer, Dierl, Huber, Tritschler, Schmidt, Schwaninger, Haering, Schleicher, Kasper et al.: Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. ... in The Journal of clinical investigation 2004
Show all 4 references for ABIN1108826
Human Polyclonal AGER Primary Antibody for EIA, IHC (p) - ABIN357685
Shanmugam, Kim, Lanting, Natarajan: Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. in The Journal of biological chemistry 2003
Show all 3 references for ABIN357685
Human Polyclonal AGER Primary Antibody for EIA, IHC (p) - ABIN359696
Miyata, Akashi, Nishida: Molecular cloning and characterization of a novel member of the MAP kinase superfamily. in Genes to cells : devoted to molecular & cellular mechanisms 1999
Show all 2 references for ABIN359696
Human Polyclonal AGER Primary Antibody for WB - ABIN2786877
Luo, Saiardi, Nagata, Ye, Yu, Jung, Luo, Jain, Sawa, Snyder: GRAB: a physiologic guanine nucleotide exchange factor for Rab3A, which interacts with inositol hexakisphosphate kinase. in Neuron 2001
Show all 2 references for ABIN2786877
Human Polyclonal AGER Primary Antibody for IHC, WB - ABIN2776917
Lieuw-a-Fa, Schalkwijk, Engelse, van Hinsbergh: Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. in Thrombosis and haemostasis 2006
Human Polyclonal AGER Primary Antibody for FACS, IHC (p) - ABIN651054
Rojas, Figueroa, Morales: Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. in Carcinogenesis 2010
Human Polyclonal AGER Primary Antibody for IF, WB - ABIN390897
Peng, Lu, Wang, Yan, Chen, Zhang, Zhang, Shen: RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. in Archives of medical research 2009
There was no association between AGER gene polymorphisms and ulcerative colitis susceptibility in the Chinese Han population.
In coronary artery disease patients RAGE may be involved in promoting epicardial adipose tissue adiposity and metabolic dysfunction, such as impaired insulin (show INS Antibodies) signaling.
Genotyping of a Euro-Brazilian population of children and adolescents with type 1 diabetes showed no significant differences in the -429T>C, -374T>A and 63 bp deletion/insertion (-407 to -345 bp) in RAGE promotor when compared to control.
Multi-walled carbon nanotube induces injury or necrosis of lung epithelial cells and DNA damage via HMGB1 (show HMGB1 Antibodies)/RAGE/TLR9 (show TLR9 Antibodies) pathway.
In conclusion, these data indicated that common polymorphisms in the AGER gene might increase the risks of breast (BC) and lung (LC) cancer .
We conclude that placental RAGE is activated during preeclampsia and that RAGE-mediated inflammation in the trophoblast involves increased pro-inflammatory cytokine secretion.
increased plasma level of soluble RAGE is a better indicator of renal function decline in diabetic CKD patients instead of non-diabetic CKD patients
Study describes evidence for the role of HMGB1 (show HMGB1 Antibodies)-RAGE and the HMGB1 (show HMGB1 Antibodies)-TLR4 (show TLR4 Antibodies) axis associated with pulmonary dysfunction and central nervous system injury. [review]
Single nucleotide polymorphisms (SNPs) rs1035798 in RAGE gene, rs2073617 and rs2073618 in TNFRSF11B (show TNFRSF11B Antibodies), and rs3732410 in Golgb1 (show GOLGB1 Antibodies) will be investigated on whether there is an association with hemorrhagic stroke (HS) in Chinese population.
These results indicate that RAGE may be a potential trigger in microvascular formation and proliferation in the development of endometrial cancer.
Our results suggested that the increased RAGE expression in inflammatory circumstances and interaction with AGEs are risk factors in decreasing of aggrecan (show ACAN Antibodies) content in nucleus pulposus.
This present study confirmed an important role of RAGE in vivo and vitro models of pulmonary fibrosis and suggested the therapeutic possibility for pulmonary fibrosis via RAGE regulation
beta-Caryophyllene protects against GalN (show GAL Antibodies)/LPS (show TLR4 Antibodies)-induced liver injury through down-regulation of the TLR4 (show TLR4 Antibodies) and RAGE signaling.
AGER and its functions to stimulate O-GlcNAcylation are important during liver tumorigenesis, when high blood glucose levels are inadequately controlled.
HMGB1 (show HMGB1 Antibodies) and its main receptor, RAGE, appear to be crucial factors in the pathogenesis of TnI (show TNNI2 Antibodies)-induced experimental autoimmune myocarditis.
Only one fragment RAGE (60-76) was shown to have a therapeutic activity improving the memory state of bulbectomized mice and leads to decreasing in the level of brain beta-amyloid.
These data implicate RAGE as a modulator of both vasoreactivity and of proliferative processes in the response of the pulmonary circulation to chronic-hypoxia.
activation of the RAGE by advanced glycation end products or other ligands suppresses NIPP1 (show PPP1R8 Antibodies) expression in diabetic nephropathy, contributes to podocyte hypertrophy, and glomerular inflammation
RAGE-/- mice showed reduced inflammation, lower Th2 cytokine production from mononuclear cells, and lower numbers of group 2 innate lymphoid cells in the lung compared with RAGE+/+ mice.
Mice expressing RAGE on hematopoietic cells, but not radioresistant structural cells, showed reduced neutrophilia and emphysematous change in the lung.
RAGE has a role in pathogenesis of emphysema in mice.
The advanced glycosylation end product (AGE) receptor encoded by this gene is a member of the immunoglobulin superfamily of cell surface receptors. It is a multiligand receptor, and besides AGE, interacts with other molecules implicated in homeostasis, development, and inflammation, and certain diseases, such as diabetes and Alzheimer's disease. Many alternatively spliced transcript variants encoding different isoforms, as well as non-protein-coding variants, have been described for this gene (PMID:18089847).
advanced glycosylation end product-specific receptor
, RAGE isoform NtRAGE-delta
, RAGE isoform sRAGE-delta
, advanced glycation end product receptor
, advanced glycosylation end product-specific receptor variant 1
, advanced glycosylation end product-specific receptor variant 3
, advanced glycosylation end product-specific receptor variant 4
, advanced glycosylation end product-specific receptor variant 5
, advanced glycosylation end product-specific receptor variant 6
, advanced glycosylation end product-specific receptor variant 7
, advanced glycosylation end product-specific receptor variant 8
, receptor for advanced glycosylation end products
, advanced glycation end-products receptor
, advanced glycosylation end product-specific receptor variant 2